News from bioinvent A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Jul 04, 2019, 07:05 ET BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
BioInvent International AB (BINV) today announced it will receive a $0.5 million milestone payment related to the acceptance by the U.S. Food and...
Jul 02, 2019, 03:11 ET Bioinvent Receives Ind Approval For Phase I/iia Trial of Anti-fcγriib Antibody
BioInvent International AB (BINV) today announces it has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an...
Jun 12, 2019, 06:03 ET BioInvent Publishes First Clinical Data From BI-1206 Phase l/lla Trials
BioInvent International AB (BINV) today announces the publication of the first data from two parallel Phase l/lla clinical trials of its lead product ...
Jun 03, 2019, 02:50 ET BioInvent Submits IND for Phase I/IIa Trial of Anti-FcγRIIB Antibody
BioInvent International AB (OMXS: BINV) today announces the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug...
May 22, 2019, 02:42 ET BioInvent Interim Report January 1 - March 31, 2019
Net sales SEK 17.4 (11.3) million Earnings after tax SEK -27.8 (-24.9) million Earnings after tax per share before and after dilution: SEK -0.08...
Apr 26, 2019, 02:56 ET BioInvent Receives €0.75 Million Milestone Under Mitsubishi Tanabe Pharma Partnership
BioInvent International AB (OMXS: BINV) announced today that it has received a €0.75 million milestone payment under its collaboration with...
Mar 26, 2019, 03:59 ET BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat...
Mar 21, 2019, 05:21 ET BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
ioInvent International AB (OMXS: BINV), focused on the discovery and development of novel and first-in-class immuno-regulatory antibody-based...
Mar 19, 2019, 06:04 ET Notice to Annual General Meeting in BioInvent International AB
The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting (the "AGM") to be ...
Mar 13, 2019, 08:20 ET BioInvent Expands U.S. Patent Protection for its F.I.R.S.T.™ Platform
BioInvent International AB (OMXS: BINV) announces today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance,...
Mar 12, 2019, 06:35 ET BioInvent Announces Publication of Review Article in Frontiers in Immunology on Resistance to Antibody Drugs
BioInvent International AB (OMXS: BINV), a company focusing on the discovery and development of novel and first-in-class immuno-modulatory antibodies ...
Feb 25, 2019, 02:28 ET Notice of Extraordinary General Meeting in BioInvent International AB
The shareholders of BioInvent International AB (publ) (BINV) Reg. No. 556537-7263, are hereby invited to attend the Extraordinary General Meeting...
Feb 25, 2019, 02:20 ET BioInvent Financial Statement January 1 - December 31, 2018
Fourth quarter 2018, October – December Net sales amounted to SEK 10.4 (13.5) million. Loss after tax SEK -32.7 (-33.3) million. Loss after tax per...
Feb 05, 2019, 02:53 ET BioInvent CSO to Present F.I.R.S.T.™ Discovery Platform at SLAS2019
LUND, Sweden, Feb. 5, 2019 BioInvent International AB (OMXS: BINV) announces today that its Chief Scientific Officer, Björn Frendéus, will hold a...
Jan 30, 2019, 03:02 ET BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma
BioInvent International AB (OMXS: BINV) announces today that the U.S. Food and Drug Administration (FDA) has granted the Company orphan designation...
Nov 20, 2018, 05:24 ET BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company
BioInvent International AB (OMXS: BINV) announced today that it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company...
Nov 13, 2018, 11:50 ET BioInvent Announces Publication of Data in Leading Cancer Journal Immunity
BioInvent International AB (OMXS: BINV) announced today the publication of data on the cellular and molecular mechanism-of-action of antibodies to...
Nov 07, 2018, 12:10 ET Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-development of a Next-generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody
BioInvent International AB (OMXS: BINV), focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat...
Oct 17, 2018, 03:57 ET BioInvent Embarks on Intensive Investor Meeting Program in the U.S., Europe, and Israel, and Posts Updated Presentation on Corporate Website
BioInvent International AB (OMXS: BINV) today announced that in connection with its intensive upcoming investor meeting program it has published the...
Oct 16, 2018, 02:54 ET BioInvent to Expand Pipeline With New Development Programs in Solid Cancer
BioInvent International AB (OMXS: BINV) today announced its intention to initiate three new clinical programs in solid cancer. In addition to the...
Dec 21, 2016, 05:14 ET BioInvent Announces Cancer Immunotherapy Research Collaboration and License Agreement With Pfizer and Issues New Shares to Pfizer
Pfizer Makes a $6 Million Equity Investment in New Shares in BioInvent BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company...
